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Microbial Engineering for Production of N-Functionalized
Amino Acids and Amines
Melanie Mindt, Tatjana Walter, Pierre Kugler, and Volker F. Wendisch*
N-functionalized amines play important roles in nature and occur, for
example, in the antibiotic vancomycin, the immunosuppressant cyclosporine,
the cytostatic actinomycin, the siderophore aerobactin, the cyanogenic
glucoside linamarin, and the polyamine spermidine. In the pharmaceutical
and fine-chemical industries N-functionalized amines are used as building
blocks for the preparation of bioactive molecules. Processes based on
fermentation and on enzyme catalysis have been developed to provide
sustainable manufacturing routes to N-alkylated, N-hydroxylated, N-acylated,
or other N-functionalized amines including polyamines. Metabolic
engineering for provision of precursor metabolites is combined with
heterologous N-functionalizing enzymes such as imine or ketimine
reductases, opine or amino acid dehydrogenases, N-hydroxylases,
N-acyltransferase, or polyamine synthetases. Recent progress and
applications of fermentative processes using metabolically engineered
bacteria and yeasts along with the employed enzymes are reviewed and the
perspectives on developing new fermentative processes based on insight
from enzyme catalysis are discussed.
1. Introduction
Natural products as well as fine and bulk chemicals often contain
N-specific modifications such as N-alkyl-, N-hydroxy-, or N-acyl-
groups. Enzymes for the synthesis of N-alkylated compounds
such as the N-methylated glycopeptide antibiotic vancomycin,
N-hydroxylated compounds such as N-hydroxy-l-pipecolic acid,
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a plant regulator of systemic acquired resis-
tance to pathogen infection, or N-acylated
compounds such as the N-acetylated hor-
mone melatonin have been identified and
characterized. While this review focuses
on the microbial engineering of bacteria
and yeasts for production of N-substituted
low-molecular-weight compounds, we also
introduce the occurrence, physiological
roles, and applications—for example, in
the pharmaceutical and fine chemical
industries—of these compounds as well as
their biosynthetic pathways and enzymes.
Where applicable, we describe metabolic
engineering strategies for the provision of
precursor metabolites and the integration
of the N-functionalizing enzymes into the
metabolism of the microbial production
host. Since Corynebacterium glutamicum is
an ideal host for production of nitrogenous
compounds and used in the industrial
million-ton-scale amino acid production,
many illustrative examples are given
for this production host. Performance parameters of illustrative
examples are summarized in Table 1.
The reader is referred to concise reviews on the chemical syn-
thesis of N-functionalized molecules[1,2] or on post-translational
modification of proteins at ɛ-amino groups of lysine residues,
for example, in collagen, or at their N-termini.[3] We will neither
cover N-phosphorylated compounds such as N-phosphocreatine
nor phosphoramidates that contain P─N bonds as in adeno-
sine 5-phosphoramidate[4] nor N-nitroso compounds such as
streptozotocin.[5]
Technological breakthroughs currently drive new develop-
ments in microbial engineering, for example, by CRISPR/Cas
genome editing, as well as in enzyme engineering, for example,
by directed evolution.[6] This prompted us to propose that com-
bining N-functionalizing enzymes with systems metabolic engi-
neering for efficient supply of their substrates may lead to the
development of fermentative processes for sustainable produc-
tion of N-alkylated, N-hydroxylated, or N-acylated bioactive com-
pounds.
2. Microbial Production of N-Alkylated Amino
Acids
N-alkylamino acids can be found in plants, mammals, and var-
ious microorganisms. They occur in proteins and peptides as
well as freely and they extend the chemical repertoire of the 20
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proteinogenic amino acids. N-alkylation increases amino acid
lipophilicity and renders proteins less prone to proteolysis. Thus,
as building blocks of peptide-based drugs they improve certain
pharmacokinetic properties of these peptidomimetics such as bi-
ological stability, improved bioavailability, or altered conforma-
tional stability.[7–9] For example, N-methylation of a synthetic
integrin ligand improved receptor selectivity and the respec-
tive cyclic pentapeptide c(Arg-Gly-Asp-d-Phe-NMeVal) was later
namedCilengitide. Specifically, docking studies indicated that re-
duced backbone flexibility of Cilengitide as consequence of N-
methylation was beneficial for the observed increased receptor
selectivity.[10,11]
Amino acid N-alkylation reactions occur abundantly for
amino acids embedded into peptides, but rarely for free amino
acids.[12,13] The methylation of synthetic peptides is performed
either at the peptide itself on solid support or by incorpora-
tion of N-methylated amino acid monomers.[14–16] Approaches
for chemical synthesis of free N-alkylated amino acids were
studied intensively. Synthetic preparation of N-alkylated amino
acids can be performed i. a. by direct alkylation of protected
amino acids, ring opening of 5-oxazolidinones, or by reductive
amination.[14,15,17] However, these methods are often limited
by low yields, dimethylation, or requirement of heavy metal
ions.[17] To overcome these disadvantages, microbial production
of N-methylated amino acids was developed recently (Figure 1).
Three independent routes have been engineered depending
either on a native pathway for C1-assimilation present in methy-
lotrophic bacteria, reductive alkylamination of 2-oxo acids by
the bacterial reductase DpkA, or by S-adenosyl-l-methionine
(SAM)-dependent methylation of the aromatic compound
anthranilate.
2.1. N-Methylation by Addition of Methylamine to Glutamate
Derivatives
Fermentative production of l-theanine and N-methylglutamate
(Figure 1A) can be realized based on a pathway for methy-
lamine assimilation found in some methylotrophic bacteria
likeMethyloversatilis universalis, Methylobacterium extorquens, and
Methylocella silvestris.[18–21] The N-methylated amino acid N-
methylglutamate serves as a key intermediate of the epony-
mous multi-step pathway of methylamine assimilation present
in some methylotrophs.[18–21] Expression of the genes cod-
ing for N-methylglutamate synthase (NMGS) (mgsABC) in
metabolically engineered Pseudomonas putida KT2440 enabled
glucose-based production of N-methylglutamate by methylam-
ination of the TCA cycle intermediate 2-oxoglutarate. Interest-
ingly, coexpression of mgsABC and gmaS, which encodes 𝛾-
glutamylmethylamide synthetase (GMAS), resulted in higher
product titers. Upon derepression of the glycerol catabolism by
deletion of regulatory gene glpR and integration of a second
copy of the endogenous glutamate dehydrogenase gene gdhA, N-
methylglutamate was produced from glycerol and methylamine
in a fed-batch bioreactor to a final titer of 18 g L−1 at a yield of
0.11 g g−1 with a volumetric productivity of 0.13 g L−1 h−1.[22]
l-theanine, a glutamine derivative ethylated at theN5-position,
is a non-proteinogenic amino acid and was first isolated from
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green tea leaves[23] and was later found also in the mushroom Xe-
rocomus badius.[24] Next to its flavor-enhancing ability, l-theanine
is thought to have favorable physiological and pharmacological
effects.[25–27] In plants, l-theanine is synthesized by addition
of ethylamine to l-glutamate in an ATP-dependent manner
catalyzed by l-theanine synthetase.[13,14] Carbon labeling ex-
periments revealed that ethylamine derives from l-alanine by
decarboxylation.[28,29] Hence, l-theanine can be isolated from
tea leaves, but low yields and high costs result in ineffective
industrial scale production.[30–32] Due to its low stability, the
plant-derived l-theanine synthetase is not used in microbial
production. However, side-activity for l-theanine synthesis
has been described for l-glutamine synthetase (EC 6.3.1.2[33]),
l-glutaminase (EC 3.5.1.2[34]), 𝛾-glutamyltranspeptidase (EC
2.3.2.2[35]), and 𝛾-glutamylmethylamide synthase (GMAS, EC
6.3.4.12[36]). Both l-glutaminase and 𝛾-glutamyltranspeptidase
transfer a glutamyl moiety to ethylamine, while l-glutamine
synthetase and GMAS catalyze alkylamidation of glutamate
in an ATP-dependent manner.[37] Various studies described
biological production of the desired compound using free en-
zymes or whole cell catalysts, either prokaryotic or eukaryotic,
but all approaches required external supply of l-glutamate.[37]
The first fermentative production of l-theanine starting from
glucose has been described recently. Expression of different 𝛾-
glutamylmethylamide synthase genes from methylotrophic
bacteria in C. glutamicum strains enabled a glucose and
ethylamine dependent fermentative production of l-theanine.
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Table 1. De novo synthesis of N-functionalized amines by (recombinant) microorganisms. Titer, yield, and volumetric productivity values of illustrative
production processes for N-functionalized amino acid and amines along with proposed production processes are listed.
Strain Product Enzyme(s) Titer
[g L−1]
Yield
[g g−1]
Productivity
[g L−1 h−1]
Fermentation
mode
References
for
established
processes
N-alkylation
C. glutamicum
a)
l-theanine GMAS 42.0 0.20 0.88 Fed-batch [39]
Pseudomons putida
b)
N-methyl-l-glutamate GMAS, NMGS 17.9 0.11 0.13 Fed-batch [22]
C. glutamicum pyruvate
producer
c) [48]
N-methyl-l-alanine DpkA 31.7 0.71 0.35 Fed-batch [43]
C. glutamicum glyoxylate
producer
d) [58]
Sarcosine DpkA 9.1 0.26 0.16 Shake flask [42]
C. glutamicum glyoxylate
producer
d) [58]
N-ethylglycine DpkA 6.1 0.17 0.11 Shake flask [42]
2-Oxoisocaproate
producer
e) [63]
N-methyl-l-leucine DpkA Hypothetical process
E. coli
f )
N-methylanthranilate 0.0029 — 0.0012 Shake flask [70]
E. coli
f )
N-methyl-O-
methylanthranilate
0.0157 — — Shake flask [70]
N-hydroxylation
l-valine producer
g) [91] N-hydroxy-l-valine CYP79D1, CYP79D2[88] Hypothetical process
l-isoleucine
producer
h) [97]
N-hydroxy-l-isoleucine CYP79D1, CYP79D2[88] Hypothetical process
l-lysine producer
i) [104] N6-hydroxy-l-lysine IucD[101] Hypothetical process
l-ornithin
producer
j) [109]
N5-hydroxy-l-ornithine PvdA[108] Hypothetical process
l-pipecolic acid
producer
k) [116]
N-hydroxy-pipecolic acid FMO01[115] Hypothetical process
Cadaverine
producer
l) [122]
N-hydroxy-cadaverine AvbB[119] Hypothetical process
Putrescine
producer
m) [112]
N-hydroxy-putrescine AvbB[119] Hypothetical process
N-acetylation
Bacillus subtillis
n)
N-acetylglucosamine GNA1[146] 131.6 0.38 1.37 Fed-batch [146]
l-glutamate
producer
o) [67]
N-acetylglutamate ArgA[167] Hypothetical process
l-ornithin
producer
j) [109]
N-acetylornithine ArgJ[170] Hypothetical process
Putrescine
producer
m) [112]
N-acetylputrescine SnaA[130] Hypothetical process
Cadaverine
producer
l) [122]
N-acetylcadaverin SnaA[130] Hypothetical process
Betaines
Actinopolyspora
halophila
p)
Glycine betaine — 13 Complex
medium
0.14 Batch [200]
Agrobacterium and
Rhizobium isolates
q)
l-carnitine — — 99.5 mol% 1.21 Fed-batch [201]
l-lysine producer
i) [104] l-carnitine N-lysine
methyltransferase[195],
carnitine biosynthetic
pathway[197]
Hypothetical process
Polyamines
S. cerevisiae
r)
Spermidine SPE1, SPE2, SPE3 0.22 2.2×10−3 0.003 Fed-batch [208]
E. coli
s)
1,3-diaminopropane Dat, Ddc 13 0.1 0.19 Fed-batch [209]
E. coli
t)
Putrescine SpeC 42.3 0.26 1.23 Fed-batch [210]
(Continued)
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Table 1. Continued.
Strain Product Enzyme(s) Titer
[g L−1]
Yield
[g g−1]
Productivity
[g L−1 h−1]
Fermentation
mode
References
for
established
processes
C. glutamicum
u)
Putrescine SpeC 19 0.16 0.55 Fed-batch [211]
C. glutamicum
v)
Cadaverine LdcC 88 0.29 2.2 Fed-batch [129]
C. glutamicum
w)
Cadaverine LdcC 103.8 0.30 1.47 Fed-batch [212]
Putrescine
producer
m) [112]
sym-homospermidine Homospermidine
synthase [225]
Hypothetical process
S. cerevisiae
x)
N-methylpyrrolinium PMT, DAO 0.017 — 0.14×10−3 Shake flask [226]
a)C. glutamicum GKG-047; b)P. putida KT2440 Δupp ΔglpR::Ptac-gdhA (pEV1-mgsABC-gmaS); c)C. glutamicum ATCC 13032 ΔaceE Δpqo ΔldhA ΔC-T ilvN ΔalaT ΔavtA;
d)C. glutamicum ATCC 13032 ΔaceB icdGTG; e)C. glutamicum ATCC 13032 ∆ltbR ∆ilvE ∆prpC1 ∆prpC2 PgltA mut_L1 (pBB1leuA EC-G462D); f)E. coli BL21(DE3) ΔtrpD ΔtyrR
ΔmetJ; g)C. glutamicum R JCM 18 229 ΔLP_ΔAc+GP_ilvNGECTM_ΔAla (pCRB-BNGECTM; pCRB-DLD); h)C. glutamicum IWJ001 (pDXW-8-cysK); i)C. glutamicum ATCC 13020
Psod lysC
T311I PsoddapB 2xddh 2xlysAΔpck homV59A PsodpycAP458S icdGTG Ptuffbp Psodtkt; j)C. glutamicum ATCCMB001ΔargFRG Pgdh4-argBA49V,M54V pgiGTG Ptuf- argCJBA49V,M54VD;
k)C. glutamicum GRLys1 ΔsugR ΔldhA ΔlysE2 (pVWEx1-lysDH-proC); l)B. methanolicus MGA3 (pBV2mp-cadA); m)C. glutamicum ATCC 13032 ΔargR ΔargF (pVWEx1-speC);
n)B. subtilis ΔnagP/ ΔgamP ΔgamA Δldh Δpta ΔglcK ΔpckA Δpyk::lox72 ΔnagAB::Pveg-yqaB, Pveg-glmS ΔgamR::lox72 ΔamyE:: sgzwf1-sgpfkA2-sgglmM2 ΔlacA::gamR-PgamA-
dCas9 ΔalsSD::lox72 (pSTg-GNA1); o)C. glutamicum ATCC 13032; triggered with ciprofloxacin; p)Actinopolyspora halophila MTCC263; q)Rhizobium sp. HK13 (DSM 2903);
r)S. cerevisiae SR8 ΔOAZ1 overexpressing SPE1,2,3 (pTPO1); s)E. coli W3110 ΔlacI thrAC1034T lysCC1055T Pppc::Ptrc PaspC::Ptrc ΔpfkA (p15DDoptpaspC); t)E. coli W3110 ΔlacI
ΔspeEΔspeGΔargIΔpuuPA PargECBH::Ptrc PspeF-potE::Ptrc PargD::Ptrc PspeC::PtrcΔrpoS (pKK117SargF); u)C. glutamicumORN1 (pVWEx1-speC-5‘ 21 -argF); v)C. glutamicum
LYS-12 bioD::Ptuf ldcC
opt ΔNCgl1469 ΔlysE Pcg2893::Psod; w)C. glutamicum PKC lysE::PH30-ldcCEc; x)S. cerevisiae BY4742 PTEF1-EcODC-TFBA1, PPGK1-AtPMT-TCYC1, PTEF1-AaDAO3-
TPRM9, PTCCTDH-SAM2-TPGI, ΔALD4, ΔALD5, ΔHFD1.
The production titer could be improved by change of the base
strain to a glutamate overproducing C. glutamicum strain[38] and
prevention of glutamate export by deletion of the l-glutamate
exporter gene yggB. A titer of 42 g L−1 was achieved in fed-batch
bioreactor cultivation in 5 L scale when gmaS fromMethylovorus
mays was expressed.[39] Biochemical characterization of both
enzymes GMAS and NMGS elaborated a small substrate spec-
trum: while GMAS accepts also l-glutamine as substrate,[40]
NMGS was described to convert some alkylamines (ethylamine,
propylamine, butylamine) with decreasing activity for increasing
alkyl moieties.[12] Thus, the access to other N-alkylated amino
acids produced via the GMAS and NMGS pathway is limited.
2.2. Reductive Alkylamination of 2-Oxo Acids Yielding
N-Alkylated Amino Acids
N-alkylamino acid dehydrogenase DpkA from Pseudomonas
species proved crucial to provide a more versatile route for the
production ofN-alkylated amino acids bymicrobial fermentation
(Figure 1B).[41–43] Natively, DpkA plays a role in degradation of
d-lysine and d-proline where it catalyzes imine reduction of the
cyclic imines piperidin-2-carboxylate and pyroline-2-carboxylate
yielding l-pipecolic acid and l-proline, respectively.[44] In addi-
tion, this imine reductase (IRED) catalyzes the reductive alky-
lamination of 2-oxo acids yielding the respective N-alkylamino
acids. It has been hypothesized that alkylamines and 2-oxo acids
may spontaneously form imines in aqueous solutions that sub-
sequently are reduced by DpkA.[45–47]
Various 2-oxo acids are present in a bacterial cell, for example,
as intermediates in glycolysis, the TCA cycle or in amino acid
biosynthesis pathways, thus, simple introduction of DpkA into
a bacterium is not sufficient for efficient and selective produc-
tion of a chosen N-alkylamino acid. It is pivotal to engineer the
bacterial production host for a) high dpkA expression and b) for
provision of high concentrations of the required 2-oxo acid.[41–43]
Fermentative production of N-methyl-l-alanine by C. glu-
tamicum involved strain engineering to ensure a) provision of
high concentrations of pyruvate from glucose and b) heterol-
ogous expression of dpkA from Pseudomonas species for N-
methylamination of pyruvate using methylamine.[43] The pyru-
vate secreting C. glutamicum strain ELB-P was chosen as a
basis.[48] This strain produced up to 17.6 g L−1 pyruvate in shake-
flask fermentations due to several modifications of the pyruvate-
converting enzymes: accumulation of pyruvate was enabled by
deletion of the pyruvate dehydrogenase subunit E1p (aceE), the
pyruvate-quinone oxidoreductase gene (pqo), the C-terminal reg-
ulatory domain of the acetohydroxyacid synthase gene (ilvN), the
lactate dehydrogenase gene (ldhA), and both genes for l-alanine
synthesizing aminotransferases (alaT for alanine aminotrans-
ferase and avtA for alanine-valine aminotransferase). In an ele-
gant manner, growth and product formation by this recombinant
C. glutamicum strain are decoupled. This concept, which was
transferred to l-lysine, l-valine, isobutanol, and 2-oxoisovalerate
production,[49–55] ensures that the strain utilizes carbon sources
like sugars for product formation, whereas acetate is required for
biomass formation. Balancing the ratios of glucose and acetate as
carbon substrates as well as media optimization with respect to
ammonium and methylammonium concentrations proved im-
portant to obtain N-methyl-l-alanine as dominant product in
high titers. Finally, transfer to fed-batch bioreactor cultivation al-
lowed for a production of 32 g L−1 N-methyl-l-alanine at a yield
of 0.7 g g−1 (glucose) and a volumetric productivity of 0.35 g L−1
h−1.[43]
Extending this concept to the microbial production of N-
alkylated glycine derivatives, that show potential as antipsychotic
drugs,[56,57] as building blocks for peptidomimetics or detergents,
involved a) strain engineering for sufficient supply of the 2-oxo
acid glyoxylate and b) engineering of DpkA for better acceptance
Biotechnol. J. 2020, 15, 1900451 1900451 (4 of 15) © 2020 The Authors. Biotechnology Journal published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.biotechnology-journal.com
Figure 1. Functionalization of amines by N-alkylation (depicted in red) can be achieved by different routes depending on the product of interest. The
ATP-dependent N-alkylation of glutamate is performed by A) 𝛾-glutamylmethylamide syntethase (GMAS) and N-methylglutamate synthase (NMGS),
B) reductive amination of 2-oxo acids by the N-methylamino acid dehydrogenase DpkA, and C) the production of O-methyl-N-methylanthranilate is
catalyzed by SAM-dependent anthranilateN-methyltransferase (NMT) and SAM-dependent anthranilateO-methyltransferase (AAMT) or by anthranilate
CoA ligase and methanol anthraniloyltransferase.
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of glyoxylate as substrate for N-alkylation.[41,42] A base strain
overproducing glyoxylate was derived from a glycolate producing
strain which lacks the glyoxylate converting malate synthase
and has low isocitrate dehydrogenase activity due to initiation
codon exchange from ATG to GTG.[58] Based on the discovery
that the imine reductase DpkA does not only accept pyruvate
and several 2-oxo acids,[46] but also glyoxylate as substrate with
good catalytic activity,[42] DpkA was integrated into the central
metabolism of the glyoxylate accumulating C. glutamicum base
strain and enabled the production of sarcosine (also known
as N-methylglycine). A final titer of 8.7 g L−1 sarcosine and a
volumetric productivity of 0.12 g L−1 h−1 were achieved in a
xylose-based process.[42] This process depended on the substrate
promiscuity of the IRED DpkA[42] and, thus, rational enzyme
engineering and subsequent characterization was employed
to develop a more efficient mutant of DpkA.[41] Mutation of a
single amino acyl residue in the substrate binding site of DpkA
(DpkAF117L) increased specific activities for reductive alkylami-
nation of glyoxylate using either methylamine or ethylamine as
substrat.[41] Based on DpkAF117L, an improved volumetric pro-
ductivity (0.16 g L−1 h−1) was achieved for sarcosine production
and fermentative production of N-ethylglycine to a final titer of
6.1 g L−1 could be established.[41] Notably, sustainable production
of sarcosine and N-ethylglycine from alkylamines and second
generation feedstocks such as rice straw hydrolysate could be
demonstrated.[41] The DpkA-based approach of N-alkylating
2-oxo acids may be diversified further. Regarding provision of
the 2-oxo acid precursor, it is conceivable that E. coli, Clostridium
thermocullum, Synechococcus elongates, and C. glutamicum strains
developed for biofuel production from 2-oxo acid precursors
can be converted to strains overproducing N-alkylated amino
acids. These strains involve 2-oxo acid decarboxylation using
2-oxoisovalerate decarboxylase KivD from Lactococcus lactis and
aldehyde reduction by an aldehyde dehydrogenase.[52,59–62] In
principle, this would only require a replacement of kivD and adhA
by dpkA and feeding alkylamines. Alternatively, strains overpro-
ducing a particular 2-oxo acid[38,55,63–69] may be used as basis.
However, it must be kept in mind that DpkA may have to be en-
gineered to ensure efficient and selectiveN-alkylamination of the
overproduced 2-oxo acid or an alternative IRED has to be used.
2.3. SAM-Dependent N-Methylation of Amino Acids
SAM-dependent N-methyltransferases have been described i.a.
for the synthesis ofN-methylanthranilate[70] and the anthranilate-
derived alkaloid 4-hydroxy-1-methyl-2-quinolone.[71] O-alkylated
N-methylanthranilates are known to have flavor and fra-
grance characteristics as well as antinociceptive and analgesic
activities,[72,73] while the group of anthranilate-derived alkaloids
include bioactive molecules which show antiseptic, convulsive,
or antineoplastic activities. The SAM-dependent N-methylation
of anthranilate is catalyzed by anthranilate N-methyltransferase
(Figure 1C). Upon expression of the respective gene from Ruta
graveolens in an engineered E. coli BL21 strain low titers of
N-methylanthranilate (0.029 g L−1) accumulated.[70] This strain
was previously optimized by deletion of anthranilate phospho-
ribosyl transferase gene trpD, and the genes tyrR and metJ
encoding negative transcriptional regulators of the aromatic
amino acid biosynthesis and SAM biosynthesis, respectively.
Similarly, low titers were obtained upon further conversion of N-
methylanthranilate to either O-methyl-N-methylanthranilate
(0.016 g L−1)[70] or 4-hydroxy-1-methyl-2-quinolone
(0.018 g L−1).[71] By contrast, O-methylanthranilate production
to high titers (5.74 g L−1) has been described as consequence
of systems metabolic engineering and the development of fed-
batch mode two-phase bioreactor cultivation with tributyrin.[74]
It has to be noted that the hydrophobicity and/or volatility of
a compound dictates its suitability for two-phase cultivations
(e.g., better suited for O-methylanthranilate and O-methyl-N-
methylanthranilate than for the charged N-methylanthranilate)
and that the overlay phase has to be chosen accordingly. How-
ever, as upscaling efficiencies of 10 to 70-fold have been observed
when moving from two-phase shake flasks to two-phase biore-
actors in the case of O-methylanthranilate [74] and patchoulol,[75]
this approach may prove crucial for commercialization.
3. N-Hydroxylating Enzymes and Their Application
in Microbial Amino Acid and Amine Production
Hydroxylation at different positions of amino acids is well-known
in nature.[76–78] While hydroxylation of aliphatic or aromatic car-
bon atoms, for example, by phenylalanine, tryptophan, or
tyrosine hydroxylases, have been studied well due to their
physiological roles in mammals as in phenylketonuria or the
biosynthesis of catecholamines or serotonin,[77] N-hydroxylases
that occur in all three domains of life have received less attention.
N-hydroxylating enzymes are involved in several biosynthesis
pathways, for example, in siderophore synthesis in plants and
bacteria, but also known for enhancing antibiotic resistance.[79,80]
3.1. N-Hydroxylation in Nature
Cytochrome P450s (CYPs, EC 1.14) and flavin dependent
monooxygenases (FMOs, EC 1.13) are known for their N-
hydroxylating activities. FMOs, for example, play a role in
the adaptation of butterflies to pyrrolizidine-alkaloid-producing
plants.[81,82] Higher resistance or nonsusceptibility against the
antibiotic rifampicin is observed inmanyNocardia isolates due to
FMO-catalyzed hydroxylation of rifampicin at theN2-position.[79]
Aerobactin is an iron chelating siderophore, which helps E. coli
and related bacteria to survive in iron-poor environments[80] and
its synthesis initiates by N-hydroxylation of the amino acid l-
lysine in an NAPDH dependent manner by the membrane-
bound FMO l-lysine N6-monooxygenase. After N6-acetylation of
N6-hydroxy-l-lysine (Section 4.1) and subsequent N1-citrylation,
aerobactin synthase ligates the resulting N1-citryl-N6-acetyl-N6-
hydroxy-l-lysine to N6-acetyl-N6-hydroxy-l-lysine yielding the di-
hydroxamate siderophore aerobactin.[83–85]
3.2. N-Hydroxylation for Microbial Production
While C-hydroxylated amino acids have been produced by micro-
bial fermentation, for example, 4-hydroxy-l-isoleucine[86] and 4-
hydroxy-l-proline,[87] no fermentative process forN-hydroxylated
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Figure 2. Hypothetical processes for production of N-acylated (depicted in blue) and N-hydroxylated (depicted in green) amino acids and amines.
N-hydroxy-l-valine and N-hydroxy-l-isoleucine formation can be catalyzed by a Cytochrome P450 from cassava, N-hydroxy-l-ornithine by l-ornithine
N5-hydroxylase PvdA from P. aeruginosa. Avaroferrin formation can proceed viaN-hydroxycadaverine andN-hydroxyputrescine formed byN-hydroxylase
AvbB from Shewanella algae, N-hydroxy-N-succinylcadaverine, and N-hydroxy-N-succinylputrescine is formed by N-succinyl transferase AvbC before
condensation by siderophore synthase AvbD. N6-hydroxy-l-lysine formation is catalyzed by N6-l-lysine hydroxylase IucD. N-hydroxy-l-pipecolic acid
formation can be catalyzed by the flavin dependentmonooxygenase FMO01 fromA. thaliana. Dashed lines refer tomultiple reaction steps and continuous
lines to one reaction.
amines or amino acids has been published. Potentially, such
processes can be envisioned, i.a. based on N-hydroxylases active
with l-valine or l-isoleucine. For example, the first step in
the biosynthesis of the cyanogenic glucosides linamarin and
lotaustralin in cassava is catalyzed by N-hydroxylating CYPs
(CYP79D1, CYP79D2) active with l-valine and l-isoleucine as
substrates (Figure 2).[88] These CYPs could be functionally ex-
pressed in the methylotrophic yeast Pichia pastoris, but not in E.
coli.[88] In principle, microbial production of N-hydroxy-l-valine
and N-hydroxy-l-isoleucine may be possible since strains of
Bacillus licheniformis, C. glutamicum, E. coli, and Saccharomyces
cerevisiae have been engineered for high titre l-valine (up to 150
g L−1) or l-isoleucine (up to 50 g L−1) production.[89–100] Likely, S.
cerevisiae is the preferred host for expression of plant CYP genes,
in particular, since functional expression of cassava CYP79D1
and CYP79D2 failed in E. coli.
The proposed concept of expressing an amine N-hydroxylase
gene in a strain overproducing the respective amine or amino
acid to enable fermentative production of the chosen N-
hydroxylated amine or amino acid may be relevant in sev-
eral instances, for example, N6-hydroxy-l-lysine, N5-hydroxy-l-
ornithine, N-hydroxypipecolic acid, N-hydroxycadaverine, or N-
hydroxyputrescine (Figure 2). Fermentative production of N6-
hydroxy-l-lysine may be based on expression of iucD from
E. coli encoding l-lysine N6-monooxygenase, which showed a
sub-millimolar KM for l-lysine,
[83,101] in an l-lysine overproduc-
ing bacterium. The annual fermentative production of l-lysine
topped 2.5 million metric tonnes in 2017[102–104] and C. glutam-
icum strains producing l-lysine to titers up to 120 g L−1 are
known.[104,105] Alternatively, other bacterial hosts such as E. coli
for glucose-based l-lysine production or Bacillus methanolicus for
l-lysine production from methanol as alternative carbon source
would be suitable.[106,107]
Access to N5-hydroxy-l-ornithine by fermentation may be-
come possible if a gene coding for an FMO with l-ornithine
N5-hydroxylating activity is expressed in an l-ornithine over-
producing strain.[108] l-Ornithine overproduction has been en-
gineered in C. glutamicum, E. coli, B. subtilis, Weissella confuse,
and S. cerevisiae.[109–114] The FMO PvdA from Pseudomonas aerug-
inosa, which is part of the biosynthetic pathway leading to the
siderophore pyoverdin, is a good candidate for fermentative pro-
duction of N5-hydroxy-l-ornithine due to its relatively low KM
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value of 0.58 mm and a high vmax of 1.34 𝜇mol min
−1 mg−1.[108]
Production of N-hydroxy-l-pipecolic acid (Figure 2) may become
possible by overexpression of the l-pipecolate N-hydroxylase
FMO1 from Arabidopsis thaliana[115] in an engineered l-pipecolic
acid producer.[116,117]
In principle, both N-hydroxycadaverine and N-
hydroxyputrescine can be accessed via fermentation em-
ploying the same FMO, that is, either PubA from Shewanella
putrefaciens[118] or AvbB from Shewanella algae[119] or GorA from
Gordonia rubripertincta.[120] Expression of one of these enzymes,
which show multi-specificity with putrescine, cadaverine, and
hexamethylenediamine, in a putrescine overproducing strain
will yield N-hydroxyputrescine, whereas N-hydroxycadaverine is
formed upon expression in a cadaverine overproducing strain
(Figure 2). Various strains for overproduction of either cadaver-
ine or putrescine are available among the species C. glutamicum,
E. coli, B. methanolicus, and Serratia proteamaculans.[112,121–128]
In C. glutamicum, cadaverine production via l-lysine decarboxy-
lase allows for high cadaverine titers without contaminating
putrescine formation,[129] and vice versa putrescine produc-
tion via ornithine decarboxylase enables high putrescine titers
without contaminating cadaverine.[130,131] Thus, these C. glu-
tamicum strains meet the prerequisite to use a multi-specific
N-hydroxylase such as GorA for exclusive production of either
N-hydroxyputrescine or N-hydroxycadaverine based on substrate
availability for GorA.
4. N-Acetylation of Amino Acids and Amines for
Microbial Production
N-acylated and especially N-acetylated amines are widespread
among bacteria and eukaryotes. N-acylation plays a role in mela-
tonin and siderophore biosynthesis, biosynthesis of bacterial
and fungal cell walls, and the exoskeleton of crustaceans, post-
translationalmodifications of proteins, or as part of detoxification
processes including antibiotic resistance.[132–136]
4.1. N-Acetylation in Nature
N-acetylation requires CoA-activated acyl-groups for transfer
to primary or secondary amino groups in proteins or other
amines. Depending on their substrate specificity amino acid N-
acetyltransferases (EC 2.3.1.1), diamine N-acetyltransferases (EC
2.3.1.57), and arylamine N-acetyltransferases (EC 2.3.1.5) can be
distinguished. Co- and post-translational N-terminal acylation of
proteins occurs in all branches of life and impacts enzymatic ac-
tivity, stability, or folding patterns of proteins significantly.[136]
The proportion of proteins partially or fully acetylated at their
N-termini is particularly large in eukaryotes: 50–70% in yeast,
72% in A. thaliana, and 80–90% in humans.[136,137] Although
underestimated for a long time, N-terminal acylation of bac-
terial proteins is of high functional relevance. Bacterial cell
walls contain polymeric peptidoglycan comprising N-acetyl-d-
glucosamine (GlcNAc) and N-acetylmuraminic acid (MurNAc)
as monomeric constituents.[138] N-acetylation of low-molecular-
weight amines is important as well, for example, N-acetylation
of serotonin is a crucial and rate limiting step for the biosyn-
thesis of melatonin, a hormone released by the pineal gland for
regulation of the sleep–wake cycle.[132,139] N-acetyl or N-succinyl
transferases also function in siderophore biosynthesis (Figure 2)
and often accept N6-hydroxylated substrates that arise from N-
hydroxylation reactions (Section 3.1). For example, formation of
N6-acetyl-N6-hydroxy-l-lysine in E. coli aerobactin biosynthesis
is catalyzed by N6-hydroxylysine N-acetyltransferase IucB.[80,85]
In pyoverdine biosynthesis, N5-formyl-N5-hydroxy ornithine and
N5-acetyl-N5-hydroxy ornithine are synthesized.[133,140] For avaro-
ferrin synthesis in S. algae (Figure 3), N-hydroxyputrescine and
N-hydroxycadaverine are succinylated by the N-succinyl trans-
ferase AvbC.[119] Antibiotic resistance may be due to N-acylation.
Aminoglycoside acetyltransferases are causal, for example, for
resistance of E. coli isolates to gentamicin and sisomicin[135] or
for ciprofloxacin resistance of clinical isolates of E. coli, Klebsiella
pneumoniae, and Enterobacter.[141]
4.2. Microbial Production of N-Acetylated Compounds
N-acetyl-d-glucosamine and its derivative N-acetyl-d-neuraminic
acid find application in pharmaceutical and health food
products.[142] N-acetylglucosamine production by S. cerevisiae
with titers up to 3.0 g L−1 in shake flask cultivation were obtained
based on systems metabolic engineering.[143] Overexpression of
the genes for glutamine-fructose-6-phosphate amidotransferase
Gfa1 and the phosphatase YqaB were combined with decreased
glucose uptake rate by overexpression of MTH1-ΔT, which
codes for a truncated glucose sensing regulator. In addition, the
pyruvate kinase-1 (Pyk1) and phosphofructokinase-1 (PFK-1)
genes were repressed by dCas9 and the gene encoding phos-
phofructokinase 2 (PFK-2) was deleted.[94,134,144] Similarly, B.
subtilis was engineered to produce 48.9 g L−1 GlcNAc at a yield
of 0.32 g g−1 glucose in fed-batch fermentation.[145] Recently,
B. subtilis has been engineered for the production of 130 g L−1
GlcNAc in 15 L fed-batch cultivation. An autonomous dual-
control system was established for balancing the metabolic flux
towards the production of GlcNAc by the application of a GlcNAc
biosensor in combination with CRISPRi-based NOT gates for
self-adjusting gene expression levels.[146] The acetyl transferase
GNA1 from S. cerevisiae was heterologously overexpressed and
high product titers were obtained by the combination of modu-
lar engineering of GlcNAc synthesis-related metabolic network,
glycolysis, and peptidoglycan synthesis, blocking sporulation,
engineering the maintenance metabolism, and blocking acetoin
overflow.[142,145,147,148] In E. coli, a straightforward strategy em-
ployed inactivation of genes involved in glucosamine transport
and catabolism, overexpression of the l-glutamine-d-fructose-
6-phosphate aminotransferase gene (glmS) and one of three
different GlcN-6-P N-acetyltransferase genes (either from S. cere-
visiae, Candida albicans, or A. thaliana). Notably, the best strain
produced 110 g L−1 GlcNAc with a yield of 0.45 g g−1 glucose in
two-phase fed batch process.[149] A comparable approach in E.
coli led to about 73 g L−1 GlcNAc.[150,151] The GlcNAc derivative
N-acetyl-d-neuraminic acid was produced by recombinant E.
coli to a titer of 13.8 g L−1 using glycerol and GlcNAc in a
pyruvate-independent biocatalytic process.[152–155]
Long-chain N-acylated aromatic amino acids are frequently
encountered in antibacterial screens of metagenomic cDNA
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Figure 3. Production of betaines and polyamines. A) Glycine betaine formation proceeds via three N-methylation (depicted in red) steps by glycine-
sarcosine methyltransferase (GSMT) and sarcosine-dimethylglycine methyltransferase (SDMT), which show overlapping substrate specificities. B) Pro-
duction of N-methylpyrrolinium: putrescine is converted to N-methylputrescine by putrescine N-methyltransferase (PMT) and further oxidized by di-
amine oxidases (DAO) to yieldN-methyl-𝛾-butyraldehyde, which spontaneously cyclizes toN-methylpyrrolinium. C) Overview of the various polyamines
discussed in the text.
libraries.[156–158] These long-chain N-acylated amino acids arise
from acylation of the respective amino acids (l-phenylalanine,
l-tyrosine, l-tryptophan, and l-arginine) activated by CoA or
acyl carrier proteins. For instance, the N-acylating enzyme NasP
uses activated fatty acids of typical chain lengths between C12–
C20.[157] While various strains for overproduction of the amino
acids l-phenylalanine, l-tyrosine, l-tryptophan, and l-arginine
are available [159–166] and the genes for N-acylating enzymes and
acyl activating enzymes are known, a production host has to be
chosen to facilitate the accumulation of the very hydrophobic
compounds in the cell membranes and to withstand the impact
of high concentrations of these antibiotics.
Amino acids such as N-acetyl-l-glutamate and N-acetyl-l-
ornithine occur, for example, as intermediates in amino acid
biosynthesis routes. In l-arginine biosynthesis, N-acetyl gluta-
mate synthase (EC 2.3.1.1) N-acetylates l-glutamate with acetyl-
CoA,[167–169] while acetylglutamate-acetylornithine transacetylase
(EC 2.3.1.35) catalyzes acetyl transfer between l-ornithine and
l-glutamate.[170,171] Production of N-acetyl-l-glutamate and N-
acetyl-l-ornithine has not been followed per se, but has been
pivotal during the optimization of strains overproducing l-
arginine,[172] l-ornithine,[109] l-proline (via the ornithine cy-
clodeaminase route),[173] or l-citrulline[174]. Interception of l-
arginine biosynthesis in a strain overproducing l-arginine to very
high titers may prove suitable, for example, for the overproduc-
tion of N-acetyl-l-glutamate. Also, in the so-called succinylase
and acetylase variants of l-lysine biosynthesis, N-succinylated
intermediates (e.g., in C. glutamicum) or N-acetylated inter-
mediates (e.g., in E. coli) occur. In C. glutamicum, tetrahy-
drodipicolinate N-succinyltransferase DapD forms l-N-succinyl-
2-amino-6-ketopimelate using succinyl-CoA as a cofactor, while
the E. coli enzyme generates the N-acetylated version of this
molecule.[175,176]
Interestingly, N-acetylation of the diamines putrescine and
cadaverine was very efficient in C. glutamicum and the
gene for spermi(di)ne N-acetyl-transferase snaA[130] had to be
deleted in putrescine and cadaverine overproducing strains to
avoid secretion of these compounds.[131,177–179] Polyamine N-
acetyltransferases are widespread and found in humans, ani-
mals, yeasts, and bacteria.[180–182] Specific processes for produc-
tion of N-acetylated polyamines have not yet been described but
appear possible given the ease of biosynthesis and excretion ofN-
acetylputrescine and N-acetylcadaverine by recombinant C. glu-
tamicum (Section 4.1).
5. Production of Betaines and Polyamines
Betaines as well as polyamines are both associated with stress
tolerance in nature.[77] Due to their unique chemical properties
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they can interact with different cell components and, for exam-
ple, function as compatible solutes and organic osmolytes. This
makes them interesting for applications in the pharmaceutical
and cosmetics industry but also for uses as platform chemicals
and building blocks in polymer industry.
5.1. Occurrence, Functions, and Applications of Betaines
Betaines are low-molecular weight zwitterionic compounds with
a negative charge and a quaternary ammonium or phosphonium
cation function (Figure 3). The positive charge cannot be bal-
anced by protonmigration. The eponymous betaine is also called
trimethylglycine or glycine betaine. Betaines may function as
compatible solutes or as methyl group donors.[183] Choline is not
a betaine sensu stricto, it is used for example as dietary supple-
ment especially for poultry feed[184] or has medical applications
as it is closely related to the neurotransmitter acetylcholine.[185]
Glycine betaine is used as methyl donor and osmolyte in animal
feed and in plants it is used to increase cold, drought, and salt
resistance, for example, to prolong storage life of iceberg lettuce.
These properties yield to further applications in the pharmaceuti-
cal, cosmetics, and fermentation industries.[186] l-Carnitine plays
an essential role in the transport of long chain fatty acids and,
thus, has many medical applications such as in the treatment of
cardiovascular diseases, as dietary supplement, or nutraceutical,
where it is being marketed to improve weight management and
exercise performance.[187]
5.2. Biosynthesis of Betaines
The quaternary ammonium groups of glycine betaine, choline,
l-carnitine, and their derivatives arise from three subsequent
N-methylation reactions catalyzed by SAM-dependent methyl-
transferases. In the case of choline, the substrate of the
SAM-dependent N-methyltransferases is ethanolamine or its
derivatives.[188–192] Choline can be converted to glycine betaine
by two consecutive oxidation reactions with betainealdehyde
as intermediate.[191] In an alternative pathway, glycine is N-
methylated three times by glycine-sarcosine methyltransferase
and sarcosine-dimethylglycine methyltransferase, which show
overlapping substrate specificity (Figure 3).[183] Biosynthesis of
l-carnitine is special as its precursor N𝜖-trimethyllysine (TML) is
formed by degradation of proteins such as histones or calmod-
ulin that were post-translationally modified by N-methylation of
lysyl residues.[193,194] TML is converted to l-carnitine in a four-
step pathway. The existence of a fungal N-methyltransferase ac-
tive with free l-lysine remains debated.[195–197] The Rubisco large
subunit methyltransferase of pea shows a strong preference for
its protein substrate, but some side activity with free l-lysine has
been observed.[198]
5.3. Fermentative Production of Betaines
Glycine betaine can be fermentatively coproduced with the dis-
accharide trehalose from acid whey, a waste product of the
dairy industry, using the extreme obligate halophile organism
Actinopolyspora halophila that produces these compounds as
compatible solutes.[199] In optimized bioreactor fermentations
about 13 g L‒1 glycine betaine and about 5 g L‒1 trehalose
accumulated.[200]
To date, the lack of an effective lysine N-methylase yielding
TML hampers development of a fermentative de novo l-carnitine
synthesis process. Since biological resolution of racemic d,l-
carnitine is not industrially attractive, current processes re-
volve around biotransformation of precursors crotonobetaine,
𝛾-butyrobetaine, and 3-dehydrocarnitine to l-carnitine with E.
coli, Proteus mirabilis, or isolates related to Agrobacterium and
Rhizobium.[187] A large-scale fed-batch biotransformation process
for the production of l-carnitine from 𝛾-butyrobetaine was de-
veloped by Lonza AG, producing >99.9% ee l-carnitine with
a 99.5% yield and a volumetric productivity of 1.2 g L−1 h−1.
This process was chosen over a continuous process making
use of cell recycling with a productivity of 5.5 g L−1 h−1 and
91% yield due to higher downstream processing costs result-
ing from the lower yield in the continuous process.[201] Biotrans-
formation of crotonobetaine using resting cells of metabolically
engineered E. coli led to a 95% yield and a maximal produc-
tivity of 9.6 g L−1 h−1 overcoming the need for anaerobic cul-
tivation conditions.[202] A novel non-fermentative approach to
carnitine production could make use of engineered halohydrin
hydrogen-halide-lyase HheB from Corynebacterium sp. N-1074
that catalyzes the conversion of 1,3-dichloro-2-propanol and hy-
drogen cyanide to R-4-chloro-3-hydroxybutyronitrile, a precursor
for chemical l-carnitine synthesis.[203]
5.4. Occurrence, Functions and Applications of Polyamines
Polyamines are alkaline organic compounds with an aliphatic,
saturated carbon backbone, at least two primary amino groups,
and a varying number of secondary amino groups. They are
applied in a wide variety of commercial applications due to
their unique combination of reactivity, basicity, and surface ac-
tivity. The main commercial interest in biogenic polyamines is
their use in polymers. Diamines can be used as monomers for
the production of polyamides, whereas higher amines can be
applied as curing agents in epoxy-resins.[204] The occurrence,
biosynthesis, and applications of diamines have been reviewed
elsewhere.[204–206] Here, we give examples for polyamines carry-
ing secondary amine groups (Figure 3), such as the linear tri-
amines and tetramines, or branched polyamines such as N4-
aminopropylspermidine, a triamine with a tertiary amine group.
These compounds arise from N-alkylation of polyamines with
primary amine groups or by condensation of several polyamine
molecules.
The linear spermidine is synthesized by spermidine syn-
thase that catalyzes the addition of a propylamine moiety
to putrescine. Propylamine is derived from decarboxylated S-
adenosyl-l-methionine (dcSAM) which can be formed by a S-
adenosylmethionine decarboxylase.[207] Spermidine is present in
all living organisms and is closely related to cell growth and
the regulation of several other biological processes. Since it was
shown to prolong lifespan and reduce inflammation, it has been
used for skin anti-ageing, human hair growth stimulation, in the
treatment of type 2 diabetes, and in increasing fruit shelf life.[208]
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5.5. Fermentative Production of Polyamines
A system for spermidine production was constructed in S.
cerevisiae by overexpressing a polyamine transporter for prod-
uct secretion and genes of the spermidine biosynthetic path-
way in addition to the disruption of a gene responsible for
feedback inhibition of the pathway. As an inhibitory effect of
glucose on spermidine production was observed, the process
was designed to use a mixture of xylose and glucose as car-
bon source. However, in a fed-batch fermentation only about
0.2 g L−1 were produced.[208] This may be due to the fact that
SAM or dcSAM have to be regenerated from methylthioadeno-
sine, which arises from dcSAM-dependent N-propylamination
of putrescine in spermidine biosynthesis. For example, the fer-
mentative 1,3-diaminopropane production by metabolically en-
gineered E. coli yielded two orders of magnitude higher titers for
1,3-diaminopropane, that is, 13 g L−1.[209] These high titers can
also be reached for putrescine production, that is, 42.3 g L−1 ob-
tained with E. coli in a fed-batch process at a yield of 0.26 g pu-
trescine per g glucose and a volumetric productivity of 1.23 g L−1
h−1.[210] A C. glutamicum fed-batch process led to 19 g L−1 pu-
trescine at a yield of 0.16 g putrescine per g glucose and a volu-
metric productivity of 0.55 g L−1 h−1.[211]
As C. glutamicum is an industrial l-lysine producer it is a suit-
able host for fermentative cadaverine production as evidenced by
cadaverine production from glucose with a titer of 88 g L−1 at
a yield of 0.29 g cadaverine per g glucose and a productivity of
2.2 g L−1 h−1.[129] Integration of the E. coli ldcC gene driven by
the tuf promoter into the lysine exporter gene lysE on the chro-
mosome of an industrial l-lysine producing C. glutamicum strain
led to the highest reported cadaverine titer of 103.8 g L−1.[212] Ca-
daverine production with alternative carbon substrates such as
xylose,[213] xylooligosaccharides,[214] cellobiose,[215] galactose (by
E. coli),[216] or methanol (by B. methanolicus)[217] has also been de-
scribed. Cadaverine production has also been shown by two novel
approaches: using synthetic mutualistic consortia consisting ei-
ther of two E. coli strains[124] or one E. coli and one C. glutamicum
strain[218] on the one hand and coproduction of cadaverine with
succinic acid, the monomeric precursors of polyamide PA5,4
on the other hand.[219] Conversion of l-lysine to cadaverine has
been shown by whole-cell-biotransformation[216,220–223] or by bio-
catalysis using catalytically active inclusion bodies of LdcC from
E. coli.[224]
Conceptionally, the efficient 1,3-diaminopropane, putrescine,
and cadaverine overproducing strains could be used as basis
for production of polyamines with secondary amine groups.
For example, the bacterial homospermidine synthase found
in many proteobacteria such as Legionella pneumophila and
P. aeruginosa condenses two molecules of putrescine to sym-
homospermidine[225] and might be expressed in a putrescine
overproducing strain to enable fermentative production of sym-
homospermidine. The recent demonstration of production of
N-methylpyrrolinium (Figure 3), the precursor of alkaloids
such as tropane alkaloids, by metabolically engineered E. coli,
and S. cerevisiae strains is important.[226] First, putrescine N-
methyltransferase from the plant Anisodus tanguticus converts
putrescine to N-methylputrescine, a polyamine with a secondary
amine group. Second, diamine oxidases (DAOs) from the re-
lated plant Anisodus acutangulus oxidize N-methylputrescine to
N-methyl-𝛾-butyraldehyde which spontaneously cyclizes to N-
methylpyrrolinium, a cyclic quaternary imine compound. Titers
of 0.002–0.017 g L−1 N-methylpyrrolinium were obtained.[226]
The discovery of an enzyme from the hyperthermophilic ar-
chaeon Pyrococcus furiosus catalyzing aminopropylation of the
polyamines agmatine, 1,3-diaminopropane, putrescine, cadav-
erine, and sym-norspermidine[227] may open ways to establish
aminopropyl derivatives of poylamines such as tridansyl-N-(3-
aminopropyl)cadaverine.
6. Conclusions and Perspectives
The fermentative production ofN-functionalized compounds has
seen first successes, but this field is still in its infancy. For indus-
trial application, key parameters such as titers, yields, and volu-
metric productivities have to be met and downstream processing
requires that the chosen product can easily be separated from
structurally similar side-products or formation of these has to be
avoided by process operation or by strain engineering.
The employment of N-functionalizing enzymes with broad
substrate specificity such as DpkA used for alkylamination
of 2-oxo acids required metabolic engineering strategies for
the selective provision of the required 2-oxo acids (e.g., DpkA
in a host engineered for pyruvate overproduction yielded N-
methyl-l-alanine, while DkpA in a host engineered for glyoxylate
production yielded sarcosine). Enzyme engineering and directed
evolution have until now played a minor role to direct substrate
selectivity towards obtaining a specific N-functionalized target
product in high purity. However, this dynamically developing
research area[6] is expected to have a major impact on realiz-
ing biocatalytic and fermentative processes for production of
N-functionalized fine chemicals.
Embedding the employed N-functionalizing enzyme into the
metabolism of the production host is critical for production to
high titers, yields, and productivities. In this respect, we foresee
major improvements of the production hosts through genetic
screens facilitated by the new CRISPR/Cas genome editing
and CRISPRi gene repression tools that can be multiplexed
for higher throughput.[228] Moreover, non-targeted approaches
such as adaptive laboratory evolution (ALE) will speed up strain
development and in combination with genome re-sequencing
the selected genetic changes can be identified. Gene targets
identified by CRISPR/Cas and CRISPRi screens as well as
genome alterations identified by genome re-sequencing of
strains selected in ALE experiments will have to be assessed
in follow-up experiments to determine if they are causal for
improved performance. This subset of genes can then be used
as basis for rational systems metabolic engineering avoiding
possible detrimental effects of bystander mutations that may
have arisen during ALE experiments.
These technological developments as well as a dramatically
growing metagenomics data base provide access to the hitherto
unexploited catalyst reservoir present in microorganisms, which
cannot be cultivated in the laboratory. They bear the potential to
inspire the development of a plethora of efficient fermentative
production processes, which would not only lead to N-alkylated,
N-hydroxylated, or N-acylated bioactive compounds, betaines,
and polyamines, but also to other N-functionalized compounds
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such as N-nitroso or N-phosphorylated compounds or phospho-
ramidates.
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